A.J.P. Yates

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

H. A. P. Pols, Dieter Felsenberg, David A. Hanley et al. · Osteoporosis International · 1999 · 594 citations

Medicine, Endocrinology, Bone Metabolism +15

Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis.

Pascale Chavassieux, M. Arlot, C.V. Reda et al. · Journal of Clinical Investigation · 1997 · 525 citations · Full text

Medicine, Orthopedic Surgery, Bone Metabolism +16

Prevention of Bone Loss with Alendronate in Postmenopausal Women under 60 Years of Age

David Hosking, Clair E.D. Chilvers, Claus Christiansen et al. · New England Journal of Medicine · 1998 · 487 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17

Low Body Mass Index Is an Important Risk Factor for Low Bone Mass and Increased Bone Loss in Early Postmenopausal Women

Pernille Ravn, Giovanni Cizza, N. H. Bjarnason et al. · Journal of Bone and Mineral Research · 1999 · 455 citations

Medicine, Endocrinology, Bone Metabolism +16

Prevention of Bone Loss With Alendronate in Postmenopausal Women Under 60 Years of Age

David Hosking, Clair Chilvers, Claus Christiansen et al. · Obstetrical & Gynecological Survey · 1998 · 211 citations

Medicine, Endocrinology, Pharmacotherapy +17